Spartalizumab
Monoclonal antibody targets PDCD1 via inhibition
Trials 64 · started per year
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-09-19 | Novartis Pharmaceuticals | Results Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma novartis.com ↗
The trial did not meet its primary endpoint of investigator-assessed progression-free survival (PFS) for patients treated with the investigational triplet therapy 1-4 . |
| 2020-08-22 | Novartis Pharmaceuticals | Results Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma novartis.com ↗
Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy spartalizumab (PDR001), in combination with the targeted therapies Tafinlar ® (dabrafenib) and Mekinist ® (trametinib), did not meet its primary endpoint of investigator-assessed progression-free survival. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-09-19 | Novartis Pharmaceuticals | Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma novartis.com ↗ |
| 2020-08-22 | Novartis Pharmaceuticals | Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma novartis.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 71 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | spartalizumab | “This study was a first in human (FIH), open-label, Phase I-Ib/II, multi-center study which consisted of a Phase I dose escalation part of sabatolimab (MBG453) as single agent,...” NCT02608268 ↗28“spartalizumab (PDR001), a high-affinity, ligand-blocking, humanized anti-PD-1 immunoglobulin G4 antibody, with lacnotuzumab (MCS110), a high-affinity, humanized monoclonal...” PMID 38721402 ↗ May 2024 “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 “A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.” PMID 32179633 ↗ Mar 2020 “Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.” PMID 35217575 ↗ Feb 2022 “Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread.” NCT03961971 ↗ “Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1).” PMID 38919826 ↗ Jun 2024 |
| Known as | ANTI-PD1 MONOCLONAL ANTIBODY PDR001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297831 ↗ |
| Known as | Espartalizumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297831 ↗ |
| Known as | NVP-LZV184 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297831 ↗ |
| Known as | PDR-001 | “PDR001 (also referred to as spartalizumab) is a humanized monoclonal antibody (mAb) directed against human programmed death-1 (PD-1) that blocks the interaction between PD-1...” NCT05210413 ↗44“This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human...” NCT04581343 ↗ “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 “Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein.” NCT07157345 ↗ |
| Known as | sparatlizumab | “We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37...” PMID 36702949 ↗ Jan 2023 |
| Known as | Spartalizumab/PDR001 | “Spartalizumab/PDR001” NCT02900664 ↗ |
| Known as | tat-βsyn-deg | “Our prior work identified tat-βsyn-deg (PDR-001), a three-segment peptide that selectively targets α-synuclein.” NCT07157345 ↗ |
| Action | Inhibit | “PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2” NCT02325739 ↗ |
| Modality | Monoclonal antibody | “PDR001 is a humanized anti-PD1 IgG4 antibody” NCT02325739 ↗ |
| Route | Intravenous | “Intravenous PDR001 was administered in a fixed dosing regimen of 300 mg iv every three weeks” NCT02325739 ↗ |
| Target | PDCD1 | “anti-PD-1 spartalizumab (PDR001)” PMID 35217575 ↗ Feb 2022 |